Literature DB >> 29520785

Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers.

Michael J Curtis1, Steve Alexander2, Giuseppe Cirino3, James R Docherty4, Christopher H George5, Mark A Giembycz6, Daniel Hoyer7,8, Paul A Insel9, Angelo A Izzo3, Yong Ji10, David J MacEwan11, Christopher G Sobey12, S Clare Stanford13, Mauro M Teixeira14, Sue Wonnacott15, Amrita Ahluwalia16.   

Abstract

This article updates the guidance published in 2015 for authors submitting papers to British Journal of Pharmacology (Curtis et al., 2015) and is intended to provide the rubric for peer review. Thus, it is directed towards authors, reviewers and editors. Explanations for many of the requirements were outlined previously and are not restated here. The new guidelines are intended to replace those published previously. The guidelines have been simplified for ease of understanding by authors, to make it more straightforward for peer reviewers to check compliance and to facilitate the curation of the journal's efforts to improve standards.
© 2018 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2018        PMID: 29520785      PMCID: PMC5843711          DOI: 10.1111/bph.14153

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  6 in total

1.  Six red flags for suspect work.

Authors:  C Glenn Begley
Journal:  Nature       Date:  2013-05-23       Impact factor: 49.962

2.  Experimental design and analysis and their reporting: new guidance for publication in BJP.

Authors:  Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath
Journal:  Br J Pharmacol       Date:  2015-07       Impact factor: 8.739

3.  Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP.

Authors:  John C McGrath; Elliot Lilley
Journal:  Br J Pharmacol       Date:  2015-05-12       Impact factor: 8.739

Review 4.  Reproducibility in science: improving the standard for basic and preclinical research.

Authors:  C Glenn Begley; John P A Ioannidis
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

5.  Announcement: Transparency upgrade for Nature journals.

Authors: 
Journal:  Nature       Date:  2017-03-15       Impact factor: 49.962

Review 6.  An investigation of the false discovery rate and the misinterpretation of p-values.

Authors:  David Colquhoun
Journal:  R Soc Open Sci       Date:  2014-11-19       Impact factor: 2.963

  6 in total
  546 in total

1.  The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease.

Authors:  Xiaoying Lian; Xiaoyuan Wu; Zhongxin Li; Yingjie Zhang; Kangkang Song; Guangyan Cai; Qinggang Li; Shupeng Lin; Xiangmei Chen; Xue-Yuan Bai
Journal:  Br J Pharmacol       Date:  2019-01-10       Impact factor: 8.739

2.  VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways.

Authors:  Carmen Del Rio; Irene Cantarero; Belén Palomares; María Gómez-Cañas; Javier Fernández-Ruiz; Carolina Pavicic; Adela García-Martín; Maria Luz Bellido; Rafaela Ortega-Castro; Carlos Pérez-Sánchez; Chary López-Pedrera; Giovanni Appendino; Marco A Calzado; Eduardo Muñoz
Journal:  Br J Pharmacol       Date:  2018-08-23       Impact factor: 8.739

3.  JQ1, a bromodomain inhibitor, suppresses Th17 effectors by blocking p300-mediated acetylation of RORγt.

Authors:  Xiunan Wang; Yan Yang; Dandan Ren; Yuanyuan Xia; Wenguang He; Qingsi Wu; Junling Zhang; Miao Liu; Yinan Du; Cuiping Ren; Bin Li; Jijia Shen; Yuxia Zhang
Journal:  Br J Pharmacol       Date:  2020-03-23       Impact factor: 8.739

4.  A novel cross-species inhibitor to study the function of CatSper Ca2+ channels in sperm.

Authors:  Andreas Rennhack; Christian Schiffer; Christoph Brenker; Dmitry Fridman; Elis T Nitao; Yi-Min Cheng; Lara Tamburrino; Melanie Balbach; Gabriel Stölting; Thomas K Berger; Michelina Kierzek; Luis Alvarez; Dagmar Wachten; Xu-Hui Zeng; Elisabetta Baldi; Stephen J Publicover; U Benjamin Kaupp; Timo Strünker
Journal:  Br J Pharmacol       Date:  2018-06-29       Impact factor: 8.739

5.  An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice.

Authors:  Weisheng Lu; Hong Tian; Peng Qian; Ying Li; Yongkang Wang; Yang Ge; Wenbo Sai; Xiangdong Gao; Wenbing Yao
Journal:  Br J Pharmacol       Date:  2020-06-07       Impact factor: 8.739

6.  Nicotinic ACh receptor α7 inhibits PDGF-induced migration of vascular smooth muscle cells by activating mitochondrial deacetylase sirtuin 3.

Authors:  Dong-Jie Li; Jie Tong; Fei-Yan Zeng; Mengqi Guo; Yong-Hua Li; Hongbo Wang; Pei Wang
Journal:  Br J Pharmacol       Date:  2018-11-04       Impact factor: 8.739

7.  Hispaglabridin B, a constituent of liquorice identified by a bioinformatics and machine learning approach, relieves protein-energy wasting by inhibiting forkhead box O1.

Authors:  Zeng-Yan Huang; Ling-Jun Wang; Jia-Jia Wang; Wen-Jun Feng; Zhong-Qi Yang; Shi-Hao Ni; Yu-Sheng Huang; Huan Li; Yi Yang; Ming-Qing Wang; Rong Hu; Heng Wan; Chan-Juan Wen; Shao-Xiang Xian; Lu Lu
Journal:  Br J Pharmacol       Date:  2018-12-04       Impact factor: 8.739

8.  Identification and pharmacological profile of SPP1, a potent, functionally selective and brain penetrant agonist at muscarinic M1 receptors.

Authors:  Lisa M Broad; Helen E Sanger; Adrian J Mogg; Ellen M Colvin; Ruud Zwart; David A Evans; Francesca Pasqui; Emanuele Sher; Graham N Wishart; Vanessa N Barth; Christian C Felder; Paul J Goldsmith
Journal:  Br J Pharmacol       Date:  2018-11-16       Impact factor: 8.739

9.  Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state.

Authors:  Chaonan Ye; Kun Han; Jinxiu Lei; Kui Zeng; Su Zeng; Haixing Ju; Lushan Yu
Journal:  Br J Pharmacol       Date:  2018-10-04       Impact factor: 8.739

10.  Improving anticancer activity towards colon cancer cells with a new p53-activating agent.

Authors:  Liliana Raimundo; Margarida Espadinha; Joana Soares; Joana B Loureiro; Marco G Alves; Maria M M Santos; Lucília Saraiva
Journal:  Br J Pharmacol       Date:  2018-09-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.